{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-248476","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2022-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.373571+00:00","generated_at":"2026-06-23T08:06:09.450918+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biomea Fusion reports BMF-219 preclinical data: HbA1c reduction of 3.5% vs. liraglutide's 1.7% in T2D rat model","bullets":["BMF-219 lowered HbA1c by 3.5% vs. liraglutide 1.7% in ZDF rat model; effect maintained through 2-week drug washout.","BMF-219 restored HOMA-B index to normal range (>201) over 4 weeks, indicating improved beta-cell function.","BMF-219 treatment resulted in 13% body weight reduction over 4 weeks and lowered total cholesterol and triglycerides.","Company reaffirms IND submission for BMF-219 in type 2 diabetes in second half of 2022.","Data presented at EASD Annual Meeting on September 20, 2022 in Stockholm, Sweden."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-248476","json":"https://secwatch.observer/filing/0001193125-22-248476.json","markdown":"https://secwatch.observer/filing/0001193125-22-248476.md","text":"https://secwatch.observer/filing/0001193125-22-248476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522248476/0001193125-22-248476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522248476/d376137d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:06:09.450918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}